UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 inhibitor will succeed ... is an IL-6 inhibiting drug that was originally developed ...

Inhibiting the entire receptor complex prevents IL-6 ... inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or disease-modifying antirheumatic drugs.

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

The discovery broadens the known spectrum of this rare disorder, emphasizing the critical role of collaboration with patient ...

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

Roche said in a statement that the drug has also been provisionally approved ... regulator to award full regulatory approval to the IL-6 inhibitor. Actemra is widely used as a treatment for ...

PALO ALTO, CA, UNITED STATES, April 25, 2025 /EINPresswire.com/ -- Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors supports potential best-in-class profile. Data presented ...

Incyte today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...